H.R. 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (H.R. 8205) aims to extend the provisions of the original ACT for ALS Act, which was signed into law in 2021. This reauthorization seeks to continue funding and support for ALS research and therapy development through fiscal year 2031. Key components include: 1) Extending grants for ALS-related research and therapy development; 2) Continuing the Public-Private Partnership for Rare Neurodegenerative Diseases to advance understanding and treatment of ALS; 3) Maintaining the FDA's five-year action plan to foster drug development and facilitate access to investigational drugs for ALS; and 4) Requiring a new Government Accountability Office (GAO) report on the implementation of ACT for ALS programs by 2030.

Supporters of H.R. 8205 commend the bill for its commitment to sustaining and advancing ALS research and treatment initiatives. They highlight the importance of continued funding and collaboration between public and private sectors to develop effective therapies for ALS. The reauthorization is seen as a crucial step in maintaining momentum in the fight against this debilitating disease.

Critics of H.R. 8205 express concerns about the allocation of federal funds and the effectiveness of existing programs under the original ACT for ALS Act. They question whether the reauthorization will lead to significant advancements in ALS treatments and advocate for a more comprehensive evaluation of the current initiatives before extending funding through 2031.

The bill, H.R. 8205, focuses on accelerating access to critical therapies for ALS, which directly intersects with the interests of the health professionals industry. The sponsor, Mike Quigley, has received substantial donations totaling $240 million from health professionals, indicating a strong financial connection to this sector. This raises concerns about potential conflicts of interest, as the bill could benefit those donors financially if it leads to increased funding or favorable regulations for ALS therapies. Additionally, the retired donor category, while significant at $75 million, does not appear to have a direct connection to the bill's subject matter, thus lessening its impact on the overall analysis.

Moreover, the lobbying activity in this area is noteworthy, with various entities involved, including undisclosed amounts from multiple organizations. The presence of lobbying from groups like Hemoglobin Oxygen Therapeutics and others suggests that there may be additional financial interests at play that could influence the legislative process. Voters should be aware of these connections as they could affect the integrity of the bill's intent and the prioritization of patient needs over donor interests.

These industries are both affected by this bill and among the sponsor's top donors.

Organizations that lobbied on issues related to this bill's policy area.

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Top industries funding Mike Quigley, ranked by total contributions.

Source: OpenSecrets.org (Center for Responsive Politics)